Another setback for Astra
Concerns about Anglo-Swedish drugs giant AstraZeneca's pipeline are likely to increase as the company abandoned work on its anti-depressant treatment TC-5214, which it developed in conjunction with US peer Targacept.
Concerns about Anglo-Swedish drugs giant AstraZeneca's pipeline are likely to increase as the company abandoned work on its anti-depressant treatment TC-5214, which it developed in conjunction with US peer Targacept.
The two companies said top-line results from the remaining Phase 3 studies did not meet the primary endpoint and regulatory filing will not be pursued.
As a result of this setback, AstraZeneca will take an intangible asset impairment charge of $50m, the remaining value in relation to TC-5214.
Subscribe to MoneyWeek
Subscribe to MoneyWeek today and get your first six magazine issues absolutely FREE

Sign up to Money Morning
Don't miss the latest investment and personal finances news, market analysis, plus money-saving tips with our free twice-daily newsletter
Don't miss the latest investment and personal finances news, market analysis, plus money-saving tips with our free twice-daily newsletter
AstraZeneca and Targacept signed a collaboration and licence agreement for the global development and commercialisation of TC-5214 back in December 2009. The initial goal for the collaboration was to develop TC-5214 as an adjunct treatment for major depressive disorder in patients with an inadequate response to a selective serotonin re-uptake inhibitor or serotonin/norepinephrine re-uptake inhibitor.
jh
Sign up for MoneyWeek's newsletters
Get the latest financial news, insights and expert analysis from our award-winning MoneyWeek team, to help you understand what really matters when it comes to your finances.
-
8 of the best houses for sale with annexes
The best houses with annexes – from a period property in the Lake District to a 13th-century house with a two-bedroom annexe in Saltwood, Kent
By Natasha Langan Published
-
Zelenskyy moves to appease Donald Trump – what happens now?
Ukraine’s president Volodymyr Zelenskyy is conceding ground to secure the least-worst deal possible, says Emily Hohler
By Emily Hohler Published